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A B S T R A C T
Background: Hypertensive heart disease (HHD) and hypertrophic cardiomyopathy (HCM) are the most
frequently encountered entities presenting left ventricular hypertrophy in routine echocardiographic
examination, and their differentiation is sometimes difﬁcult. Abnormalities in right ventricular (RV)
myocardium have been reported frequently in patients with HCM more than in those with HHD. We
therefore hypothesized that tricuspid annular motion (TAM) velocity determined by pulsed tissue
Doppler echocardiography can be used to detect RV dysfunction in HCM and discriminate these
etiologies.
Methods: TAM velocities were compared among clinically stable patients with 60 HCM and 60 HHD
patients as well as 60 age-matched healthy controls. Peak systolic, early diastolic (TAM-e0), and atrial
systolic velocities were measured. RV myocardial performance index was measured by tissue Doppler
method. To more accurately differentiate HCM from HHD, electrocardiographic ﬁndings and brain
natriuretic peptide levels, which can both be examined simply and noninvasively, were investigated in
addition to echocardiography.
Results: RV wall thickness of the HCM group was greater than the HHD group (p = 0.092), while there
was no signiﬁcant difference in RV myocardial performance index between the HCM and HHD groups
(p = 0.606). TAM-e0 was signiﬁcantly lower in the HCM group than in HHD and control groups (p = 0.001).
To differentiate HCM from HHD, TAM-e0 was a powerful predictor as per multivariate logistic regression
analysis (hazard ratio, 0.665; p < 0.001) of parameters other than those of left ventricular parameters,
and the area under the receiver operating characteristic curve (AUC) was 0.686 and the best cut-off value
was 8.0 cm/s (62% sensitivity, 65% speciﬁcity). Multivariate logistic analysis revealed that
electrocardiographic ST–T changes were the next most effective marker for differentiating HCM after
TAM-e0. When TAM-e0 and ST–T changes were combined, the AUC increased to 0.748.
Conclusions: TAM-e0 is a potentially useful index to differentiate HCM from HHD.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) and hypertensive heart
disease (HHD) are common presentations of left ventricular (LV)
hypertrophy in routine echocardiographic examination [1], and it
is sometimes difﬁcult to differentiate between them [2,3].* Corresponding author at: Department of Cardiovascular Medicine, Tokushima
University Hospital, 2-50-1 Kuramoto, Tokushima 770-8503, Japan.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsApproximately 44% patients with HCM present with right ventricu-
lar (RV) hypertrophy (RVH) [4]. Although RVH can occur in patients
with HHD [5], an autopsy study revealed an increased incidence of
abnormalities in the RV myocardium in patients with HCM than in
those with HHD [6], indicating a potential difference in RV function.
The following parameters of RV systolic function were
commented on in the American Society of Echocardiography
guideline: peak systolic velocity of tricuspid annular motion
(TAM), RV myocardial performance index (RVMPI), tricuspid
annular plane systolic excursion, fractional area change, and RV
strain [7]. Among these indices, the TAM velocity by pulsed tissue
Doppler echocardiography (TDE) is a simple and reproducible reserved.
Table 1
Criteria for electrocardiographic abnormalities.
P-wave abnormalities
Negative portion of the P wave in lead V1 0.1 mV in depth and 0.04 s in
duration, or peaked P wave in leads II and III or V1 0.25 mV in amplitude.
Abnormal Q waves
0.04 s in duration or 25% of the height of the ensuing R wave or a QS pattern
in two or more leads.
Increased QRS voltage
Amplitude of R or S wave in limb leads 2 mV, S wave in lead V1 or V2 3 mV, or
R wave in lead V5 or V6 3 mV.
Increased QRS duration
QRS duration >0.1 s.
ST–T changes
ST-segment depression or T-wave ﬂattening or inversion in two or more leads.
Conduction abnormalities
Right or left bundle branch block, or ﬁrst-degree atrioventricular block.
Right ventricular hypertrophy (RVH)
If any of the following three requirements were met: (1) R/S ration in lead V5 or
V6 <1, (2) right axis deviation >908, or (3) R/S ratio >1 and negative T wave in
lead V1.
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equipment [7]. Therefore, we hypothesized that TAM velocity
may help in differentiating HCM from HHD.
Methods
Study population
From 12,276 subjects who underwent echocardiography at the
Ultrasound Examination Center of Tokushima University Hospital
between December 2009 and December 2012, 70 HCM and 60 HHD
patients who met the following criteria were randomly selected: (1)
sinus rhythm, (2) LV ejection fraction of at least 55%, (3) without
more than moderate valvular heart disease, (4) without coronary
artery disease, (5) without pulmonary hypertension, and (6) without
LV outﬂow tract obstruction. HCM and HHD were diagnosed as per
the American College of Cardiology Foundation/American Heart
Association guidelines [8] criteria using family history, past history,
echocardiography [9,10], electrocardiography [11], coronary angi-
ography, endomyocardial biopsy [12], magnetic resonance imaging
[13], and genetic testing [14]. Coronary artery disease was conﬁrmed
by past history or coronary angiography. Pulmonary hypertension
was conﬁrmed by systolic pulmonary artery pressure 40 mmHg.
Ten HCM patients concomitant with hypertension were excluded.
Thus, 60 patients with HCM were analyzed. LV geometry in HCM was
classiﬁed by Maron’s classiﬁcation [3].
Patients without abnormal electrocardiographic and echocar-
diographic ﬁndings were randomly extracted from a pool of
patients who were referred to our Ultrasound Examination Center
between August 2012 and December 2012 for presurgical cardiac
evaluation before noncardiac surgery. In order to co-ordinate ages
for the purpose of comparison between patients with HCM and
HHD, 60 of these patients aged 61  5 years were used as normal
controls. The study protocol was approved by the ethics committee of
the Tokushima University Hospital, and informed consent was
obtained from all subjects.
Echocardiography
Echocardiographic examination was performed by high-end
machine (Vivid E9, GE Healthcare, Horten, Norway; iE33, Philips
Healthcare, Andover, MA, USA; Aplio 80, Toshiba Medical, Tochigi,
Japan; ProSound a-10, Hitachi-Aloka Medical, Tokyo, Japan).
Echocardiographic examinations were performed by six experi-
enced sonographers who were blinded to the present study
protocol but unblinded to the clinical information. LV wall
thickness of interventricular septal wall and posterior wall were
measured from short-axis view. LV mass index was measured by
M-mode echocardiography in HHD and controls and by truncated-
ellipsoid method in HCM [9]. M-mode echocardiography was used
to obtain LV end-diastolic and end-systolic diameters and left atrial
(LA) diameter. LV and LA volumes were calculated using the
modiﬁed Simpson’s rule from apical two- and four-chamber views.
Pulsed Doppler indices were measured in the apical four-chamber
view. Systolic pulmonary artery pressure (sPAP) was estimated by
sum of peak tricuspid regurgitation pressure gradient measured
with continuous-wave Doppler echocardiography and mean right
atrial pressure. Mean right atrial pressure was estimated by
inferior vena cava size and collapsibility as per previous guideline
[7]. RV free wall thickness was measured at end-diastole by
M-mode echocardiography from left parasternal window. From
recordings of transmitral ﬂow velocity pattern, the peak early (E)
and late (A) diastolic ﬂow velocities, and E-wave deceleration time
were measured. From pulmonary venous ﬂow velocity pattern,
peak systolic (PVS), peak diastolic (PVD), and atrial reversal (PVA)
ﬂow velocities were obtained.After conventional echocardiographic examination, TDE was
performed from an apical four-chamber view to obtain mitral
annular motion (MAM) velocity of the lateral side and TAM velocity
of the RV free wall side. Peak systolic MAM velocity (MAM-s0), peak
early diastolic MAM velocity (MAM-e0), and peak atrial systolic MAM
velocity (MAM-a0) were recorded and measured [15]. TAM velocities
were measured and assessed in accordance with the guideline for
the echocardiographic assessment of the right heart in adults [7],
and peak systolic (TAM-s0), early diastolic (TAM-e0), and atrial
systolic (TAM-a0) velocities were measured. In addition, RVMPI was
measured by TDE [7].
Electrograph and biochemical data
To more accurately differentiate HCM from HHD, electrocar-
diographic ﬁndings and brain natriuretic peptide (BNP) levels, which
can both be examined simply and noninvasively, were investigated
in addition to echocardiography [11,16]. Immediately before
echocardiographic examination, patients had their blood drawn
and underwent 12-lead electrocardiography. BNP levels were
measured after quickly centrifuging collected blood. For the 12-
lead electrocardiography, seven criteria (Table 1) were investigated
to differentiate HCM and HHD [11,17]: (1) P wave abnormalities, (2)
abnormal Q waves, (3) increased QRS voltage, (4) increased QRS
duration, (5) ST–T changes, (6) conduction abnormalities, and (7)
RVH.
Statistical analysis
Data analysis was performed using the SPSS software (version
19.0.0.2; IBM Corporation, Armonk, NY, USA). Data are presented
as mean  standard deviation (SD) for continuous variables and as
percentages for categorical variables. Intraclass correlation coefﬁ-
cients and paired Student’s t-test were used to assess reproducibility
of TAM-e0. Comparisons among more than three groups were made by
one-way analysis of variance, followed by Tukey’s honestly signiﬁ-
cant difference test. Comparisons of BNP levels between HCM and
HHD groups were made by the unpaired Student’s t-test or Mann–
Whitney test. Furthermore, categorical variables were compared
using the x2 test. To identify predictors that could accurately
differentiate between HCM and HHD and identify HCM more
conclusively than abnormal echocardiographic LV geometry, we
performed receiver operating characteristic (ROC) curve and logistic
regression analysis for parameters other than those of echocardio-
graphic LV geometry. Multiple regression analysis was used to
identify the determinant of the diagnosis and was performed
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Statistical signiﬁcance was set at p < 0.05 for all examined data.
Reproducibility of TAM-e0
Ten HCM patients and ten HHD patients were randomly
selected, and the reproducibility of TAM-e0 was assessed. TAM-e0
was measured by two independent investigators in a blinded
fashion. Intraobserver intraclass correlation coefﬁcient was 0.98
for TAM-e0. The mean difference between two measurements was
0.1  0.6 (p = 0.629) for TAM-e0. Interobserver intraclass correlation
coefﬁcient was 0.98 for TAM-e0. The mean difference between two
measurements was 0.2  0.6 (p = 0.124) for TAM-e0.
Results
Backgrounds of subjects
No signiﬁcant differences were observed with regard to age,
gender, body surface area, or heart rate among HCM, HHD, and age-
matched normal controls (Table 2). The HHD group exhibited
higher systolic and diastolic blood pressures compared with HCM
and control groups. Most of the patients with HCM received low-
dose angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers, and beta blockers. Maron’s classiﬁcation in HCM
was as following: 9 patients were type I (hypertrophy conﬁned to
the anterior portion of the ventricular septum), 5 patients were
type II (hypertrophy involving the anterior and posterior septum),
34 patients showed type III (hypertrophy involving the anterior
and posterior septum as well as the lateral free wall), 3 patients
were type IV (hypertrophy involving LV regions other than the
anterior septum and the posterior wall), and 9 patients were apical
hypertrophy.
Echocardiographic characteristics
Two-dimensional and Doppler echocardiographic ﬁndings
were compared among three groups in Table 3. The HHD group
exhibited a signiﬁcantly larger LV end-diastolic volume compared
with HCM while no differences were observed among all threeTable 2
Comparisons of patients’ backgrounds among three groups.
HCM
(n = 60)
HHD
(n = 60)
Age (years) 61  16 64  14 
Male, n (%) 36 (60.0) 34 (56.6) 
Body surface area (m2) 1.61  0.21 1.64  0.19 
Heart rate (beats/min) 63  11 66  10 
Systolic blood pressure (mmHg) 121  14 153  26 
Diastolic blood pressure (mmHg) 67  11 81  18 
Medications, n (%)
Angiotensin-converting enzyme inhibitors 3 (5.0) 4 (6.7) 
Angiotensin receptor blockers 12 (20.0) 33 (55.0) 
Beta blockers 25 (41.7) 11 (18.3) 
Calcium channel blockers 0 (0) 44 (73.3) 
Diuretics 4 (6.7) 9 (15.0) 
Electrocardiography, n (%)
P wave abnormalities 26 (43.3) 25 (41.7) 
Abnormal Q waves 3 (5.0) 2 (3.3) 
Increased QRS voltage 51 (85.0) 49 (81.7) 
Increased QRS duration 21 (35.0) 20 (33.3) 
ST–T changes 47 (78.3) 30 (50.0) 
Conduction abnormalities 13 (21.7) 9 (15.0) 
RVH 3 (5.0) 2 (3.3) 
Biochemical date
BNP (pg/ml) 199.2  175.7 135.5  134.1 
Data are expressed as mean  standard deviation or number (%). HCM, hypertrophic card
BNP, brain natriuretic peptide.groups in LV ejection fraction. There were no signiﬁcant differences
in both LV mass index and LA volume index between the HCM and
HHD groups. The HCM and HHD groups exhibited signiﬁcantly
greater RV wall thickness compared with control group and RV
wall thickness of the HCM group was greater than the HHD group.
Doppler echocardiography of the left side of the heart revealed
that the E was not signiﬁcantly different among all three groups,
whereas the A was signiﬁcantly higher in the HHD group than in
HCM and control groups. The E/A ratio in the HHD group was
signiﬁcantly smaller than that in the HCM and control groups. The
PVS in the HCM group was signiﬁcantly lower than that in the
HHD group, but no signiﬁcant difference was observed among all
three groups with regard to the PVD. These results indicate that
PVS/PVD ratio in the HCM group was signiﬁcantly smaller
compared with that in the HHD group. In addition, MAM-e0 in
the HCM and HHD groups was signiﬁcantly lower compared with
that in the control group. Finally, MAM-E/e0 in the HCM and HHD
groups was signiﬁcantly higher compared with that in the control
group. However, neither MAM-e0 nor MAM-E/e0 was signiﬁcantly
different between the HCM and HHD groups. Doppler echocardi-
ography of the right heart revealed that the HCM and HHD groups
exhibited signiﬁcantly greater sPAP compared with control
group. RVMPI in the HCM and HHD groups was signiﬁcantly
higher compared with that in the control group. However, neither
sPAP nor RVMPI was signiﬁcantly different between the HCM
and HHD groups. TAM-s0 and TAM-a0 in the HCM group was
signiﬁcantly lower compared with that in the HHD group. Finally,
TAM-e0 in the HCM group was signiﬁcantly lower compared with
that in the HHD and control groups. Representative recordings of
TAM velocity in the HCM, HHD, and control groups are shown
in Fig. 1.
Characteristics of electrocardiography and biochemical data
In electrocardiographic ﬁndings, increased QRS voltage was
most frequently observed in both the HCM and HHD groups, and
ST–T changes followed (Table 2). Only ST–T changes exhibited a
higher prevalence rate in the HCM group than in the HHD group.
BNP levels were signiﬁcantly higher in the HCM group than in the
HHD group.Control
(n = 60)
HCM vs. HHD
p-Value
HCM vs. control
p-Value
HHD vs. control
p-Value
61  5 0.386 0.979 0.286
36 (60.0) 0.928 1.000 0.928
1.67  0.18 0.722 0.208 0.622
64  2 0.261 0.869 0.537
125  13 <0.001 0.970 <0.001
75  9 <0.001 0.030 0.082
0 (0) 0.884 0.333 0.144
0 (0) <0.001 0.010 <0.001
0 (0) 0.001 <0.001 0.018
0 (0) <0.001 0.938 <0.001
0 (0) 0.173 0.323 0.004
0 (0) 0.973 <0.001 <0.001
0 (0) 0.844 0.221 0.509
0 (0) 0.823 <0.001 <0.001
0 (0) 0.970 <0.001 <0.001
0 (0) <0.001 <0.001 <0.001
0 (0) 0.485 0.001 0.028
0 (0) 0.844 0.221 0.509
– 0.027 – –
iomyopathy; HHD, hypertensive heart disease; RVH, right ventricular hypertrophy;
Table 3
Echocardiographic characteristics.
HCM
(n = 60)
HHD
(n = 60)
Control
(n = 60)
HCM vs. HHD
p-Value
HCM vs. control
p-Value
HHD vs. control
p-Value
LVEDV (ml) 77  25 88  25 84  19 0.025 0.236 0.574
LVESV (ml) 26  9 29  10 29  7 0.074 0.102 0.989
LV ejection fraction (%) 66  5 67  5 65  3 0.829 0.292 0.095
LV mass index (g/m2) 133  46 126  30 75  12 0.451 <0.001 <0.001
Relative wall thickness 0.60  0.17 0.49  0.08 0.36  0.04 <0.001 <0.001 <0.001
LAV index (ml/m2) 34  11 32  10 23  4 0.482 <0.001 <0.001
RV wall thickness (mm) 3.4  1.3 3.0  0.9 1.7  0.4 0.092 <0.001 <0.001
sPAP (mmHg) 26  6 26  5 23  5 0.994 0.034 0.044
E (cm/s) 63  18 61  16 62  14 0.717 0.959 0.870
DCT (ms) 243  71 239  68 239  50 0.954 0.955 1.000
A (cm/s) 71  25 82  17 67  13 0.008 0.478 <0.001
E/A ratio 1.1  0.7 0.8  0.2 1.0  0.3 0.001 0.385 0.049
PVS (cm/s) 55  16 64  14 59  11 0.001 0.237 0.137
PVD (cm/s) 42  12 40  12 40  10 0.668 0.439 0.927
PVS/PVD ratio 1.4  0.5 1.6  0.4 1.5  0.4 0.003 0.139 0.346
PVA (cm/s) 28  9 28  9 28  6 0.998 0.965 0.945
MAM-s0 (cm/s) 7.6  2.4 8.3  2.1 10.0  2.2 0.191 <0.001 <0.001
MAM-e0 (cm/s) 7.2  2.8 7.4  2.3 10.0  2.3 0.869 <0.001 <0.001
MAM-a0 (cm/s) 9.1  3.2 10.7  2.5 10.7  2.4 0.005 0.003 0.992
MAM-E/e0 9.8  4.1 8.9  3.8 6.5  1.8 0.262 <0.001 0.001
TAM-s0 (cm/s) 11.3  2.5 12.6  2.7 12.2  2.2 0.015 0.141 0.639
TAM-e0 (cm/s) 7.4  2.2 8.9  2.5 9.4  2.3 0.001 <0.001 0.475
TAM-a0 (cm/s) 12.8  3.3 14.9  3.8 13.1  2.6 0.002 0.894 0.009
RVMPI 0.51  0.15 0.53  0.17 0.38  0.09 0.606 <0.001 <0.001
Data are expressed as mean  standard deviation. HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; LVEDV, left ventricular end-diastolic volume; LVESV,
left ventricular end-systolic volume; LV, left ventricular; LAV, left atrial volume; RV, right ventricular; sPAP, systolic pulmonary artery pressure; E, early diastolic transmitral
ﬂow velocity; A, late diastolic transmitral velocity; DCT, deceleration time of early diastolic transmitral ﬂow; PVS, systolic pulmonary venous ﬂow velocity; PVD, diastolic
pulmonary venous ﬂow velocity; PVA, pulmonary venous atrial reversal ﬂow velocity; MAM, mitral annular motion; TAM, tricuspid annular motion; s0 , peak systolic velocity; e0 ,
peak early diastolic velocity; a0 , peak atrial systolic velocity; RVMPI, right ventricular myocardial performance index.
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We performed ROC and logistic regression analysis for param-
eters other than those of echocardiographic LV geometry. TAM-e0
exhibited the largest area under the curve (AUC) among all variables
(Table 4). AUC for TAM-e0 was 0.686, with a 95% conﬁdence interval
(CI) of 0.592–0.781 (p < 0.001). The best cut-off value for TAM-e0 to
identify HCM was 8.0 cm/s or less, with a sensitivity of 62% and a
speciﬁcity of 65% (Fig. 2). Results of univariate logistic regression
analysis and multiple regression analysis are presented in Table 5.
Multiple regression analysis indicated that ST–T changes were the
next most effective marker for differentiating HCM after TAM-e0.
When TAM-e0 and ST–T changes were combined, the AUC increased
to 0.748 (95% CI 0.659–0.836, p < 0.001, Fig. 2).
Discussion
TAM-e0 in the HCM group was signiﬁcantly lower compared
with that in the HHD and control groups. Multivariate logisticFig. 1. Representative recordings of tricuspid annular motion velocities in the HCM, HHD
disease; s0 , peak systolic velocity; e0 , peak early diastolic velocity; a0 , peak atrial systolregression analysis revealed that TAM-e0 was the most powerful
predictor of HCM over HHD. We concluded that the TAM-e0 is the
index for differentiating these two entities.
Comparison of echocardiographic parameters between HCM and HHD
The LV mass index and LA volume index were signiﬁcantly higher
whereas MAM-e0 were signiﬁcantly lower in HCM and HHD groups
compared with the control group (Table 3). This indicates that
patients with HCM and HHD presented with LV diastolic dysfunction
[15]. However, E/A ratio of patients with HCM and HHD was
between 0.8 and 1.5, with no signiﬁcant difference between both
patient groups with regard to deceleration time of the E wave, which
indicates no difference in the grading of LV diastolic abnormalities
[15]. Conversely, all TAM velocity measurements were signiﬁcantly
lower in the HCM group than in the HHD group.
HHD usually results from long-term hypertension, whereas
HCM results from genetic mutations [18] and typically occurs in
younger patients when compared with HHD [19]. In addition to the, and control groups. HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart
ic velocity.
Table 4
Receiver operating characteristic curve analysis.
Variable Area under
the curve
95% CI p-Value
Echocardiography
RV wall thickness (mm) 0.557 0.453–0.661 0.281
sPAP (mmHg) 0.500 0.396–0.604 1.000
LAV index (ml/m2) 0.556 0.452–0.660 0.293
E (cm/s) 0.537 0.433–0.641 0.487
DCT (ms) 0.516 0.412–0.620 0.759
A (cm/s) 0.634 0.534–0.735 0.011
E/A ratio 0.597 0.492–0.702 0.067
PVS (cm/s) 0.668 0.572–0.765 0.001
PVD (cm/s) 0.550 0.447–0.654 0.342
PVS/PVD ratio 0.650 0.552–0.748 0.005
PVA (cm/s) 0.502 0.398–0.605 0.975
MAM-s0 (cm/s) 0.602 0.499–0.704 0.055
MAM-e0 (cm/s) 0.553 0.448–0.657 0.317
MAM-a0 (cm/s) 0.658 0.560–0.756 0.003
MAM-E/e0 0.579 0.476–0.681 0.137
TAM-s0 (cm/s) 0.627 0.528–0.726 0.016
TAM-e0 (cm/s) 0.686 0.592–0.781 <0.001
TAM-a0 (cm/s) 0.657 0.560–0.755 0.003
RVMPI 0.541 0.437–0.645 0.439
Electrocardiography
P wave abnormalities 0.508 0.405–0.612 0.875
Abnormal Q waves 0.508 0.405–0.612 0.875
Increased QRS voltage 0.517 0.413–0.620 0.753
Increased QRS duration 0.508 0.405–0.612 0.875
ST–T changes 0.642 0.542–0.741 0.007
Conduction abnormalities 0.533 0.430–0.637 0.529
RVH 0.508 0.405–0.612 0.875
Biochemical date
BNP (pg/ml) 0.632 0.533–0.732 0.012
CI, conﬁdence interval; RV, right ventricular; sPAP, systolic pulmonary artery
pressure; LAV, left atrial volume; E, early diastolic transmitral ﬂow velocity; A,
late diastolic transmitral velocity; DCT, deceleration time of early diastolic
transmitral ﬂow; PVS, systolic pulmonary venous ﬂow velocity; PVD, diastolic
pulmonary venous ﬂow velocity; PVA, pulmonary venous atrial reversal ﬂow
velocity; MAM, mitral annular motion; TAM, tricuspid annular motion; s0 , peak
systolic velocity; e0 , peak early diastolic velocity; a0 , peak atrial systolic velocity;
RVMPI, right ventricular myocardial performance index; RVH, right ventricular
hypertrophy; BNP, brain natriuretic peptide.
Fig. 2. Receiver operating characteristic curves for diagnosis of hypertrophic
cardiomyopathy. AUC, area under the curve; TAM-e0 , peak early diastolic velocity of
tricuspid annular motion.
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by LV relaxation abnormality may be associated with exaggerated
RV hypertrophy in HCM compared with HHD. In animal experi-
ments, RV hypertrophy is more likely to occur at younger age [20],
and once RV hypertrophy occurs, RV compliance drops and RV
relaxation deteriorates [21]. RV relaxation may be more deterio-
rated in HCM because RV hypertrophy presents at a younger age
than for HHD. According to a previous study, right-sided ﬁlling
pressure can be estimated from tricuspid E/e0; thus, TAM-e0 is
considered to represent ventricular relaxation the same as MAM-e0
[22]. In addition, TAM-e0 changed with gender and age in similar
patterns to MAM-e0, suggesting common effects of gender and
aging [23–25]. Thus, we conﬁrmed that TAM-e0 was lower in the
HCM group compared with the HHD group, indicating that RV
relaxation was more depressed in the HCM group.
Strain analysis has been reported as useful in the evaluation of
right ventricular function [26]. However, strain analysis requires
special equipment for acquiring and analyzing echocardiographic
images. On the other hand, the TAM velocities are more convenient
indices that can be measured using widely available ultrasound
machines.
Comparison of electrocardiographic and biochemical parameters
between HCM and HHD
There were no differences in prevalence rates between the HCM
and HHD groups for any of the electrocardiogram ﬁndings otherthan ST–T changes. The different prevalence rate of ST–T changes
was likely due to some patients presenting partial wall thickness
(e.g. apical hypertrophic cardiomyopathy). This suggests that
many HCM patients may have developed conditions such as
primary ST–T changes due to ischemia of the subendocardial layer
[27], or secondary ST–T changes due to ventricular conduction
delay [28]. BNP levels were signiﬁcantly higher in HCM group than
in HHD group. This may have been because ventricular wall stress
in HCM group was higher than in HHD group [16]. Although we did
not examine it in the present study, high-sensitivity cardiac
troponin T (hs-cTnT) has been used as a marker for cardiac
myocyte injury in HCM [29]. Thus, hs-cTnT could be a candidate for
a differential marker between HCM and HHD.
Diagnosis of HCM
The key predictor of HCM in patients, where both HCM and
HHD are suspected, was TAM-e0 in our study (Tables 4 and 5).
Family history and past history are the important factors to
distinguish HCM from HHD in the majority of cases. We
demonstrated that combination diagnosis with low TAM-e0 and
ST–T changes was useful for differentiating HCM. Based on this, we
propose a clinical method to approach patients with unknown LV
hypertrophy (Fig. 3).
Limitations
First, TDE is less reproducible for nonbasal segments and is
angle-dependent. Moreover, it assumes that the function of a
single segment represents the function of the entire right ventricle,
which is not likely in conditions that include regionality [7].
Second, patients with HCM sometimes have concurrent hyperten-
sion. One study reported almost no differences in other clinical or
sonographic characteristics, including those for RV, between
patients with asymmetric septal hypertrophy with and without
hypertension [30]. Therefore, although hypertension exacerbates
LV hypertrophy, these patients can probably be grouped with
patients with HCM. Third, TAM-e0 decreases with aging and
exhibits gender differences [23–25]. However, our sample size was
insufﬁcient to allow us to consider age and gender for statistical
analysis. Finally, our data did not contain the RV echocardiographic
Table 5
Univariate and multiple regression analyses for the diagnosis of hypertrophic cardiomyopathy.
Variable Univariate Multivariate
Odds ratio 95% CI p-Value Odds ratio 95% CI p-Value
Echocardiography
RV wall thickness (mm) 1.356 0.959–1.918 0.085
sPAP (mmHg) 1.003 0.939–1.072 0.921
LAV index (ml/m2) 1.018 0.983–1.055 0.323
E (cm/s) 1.008 0.987–1.030 0.459
DCT (ms) 1.001 0.996–1.006 0.787
A (cm/s) 0.977 0.996–0.995 0.011
E/A ratio 4.774 1.570–14.517 0.006 6.431 1.406–29.416 0.016
PVS (cm/s) 0.959 0.934–0.985 0.002
PVD (cm/s) 1.013 0.982–1.045 0.419
PVS/PVD ratio 0.291 0.125–0.674 0.004 0.378 0.137–1.043 0.060
PVA (cm/s) 0.999 0.960–1.039 0.952
MAM-s0 (cm/s) 0.867 0.737–1.021 0.087
MAM-e0 (cm/s) 0.965 0.837–1.112 0.624
MAM-a0 (cm/s) 0.823 0.719–0.942 0.005
MAM-E/e0 1.067 0.970–1.172 0.181
TAM-s0 (cm/s) 0.826 0.712–0.957 0.011
TAM-e0 (cm/s) 0.744 0.625–0.884 0.001 0.665 0.540–0.819 <0.001
TAM-a0 (cm/s) 0.846 0.756–0.946 0.003
RVMPI 0.387 0.042–3.537 0.400
Electrocardiography
P wave abnormalities 1.071 0.519–2.208 0.854
Abnormal Q waves 1.526 0.246–9.478 0.650
Increased QRS voltage 1.272 0.485–3.337 0.625
Increased QRS duration 1.077 0.506–2.291 0.847
ST–T changes 3.615 1.631–8.013 0.002 3.794 1.509–9.541 0.005
Conduction abnormalities 1.567 0.614–4.003 0.348
RVH 1.526 0.246–9.478 0.650
Biochemical date
BNP (pg/ml) 1.003 1.000–1.005 0.034
CI, conﬁdence interval; RV, right ventricular; sPAP, systolic pulmonary artery pressure; LAV, left atrial volume; E, early diastolic transmitral ﬂow velocity; A, late diastolic
transmitral ﬂow velocity; DCT, deceleration time of early diastolic transmitral ﬂow; PVS, systolic pulmonary venous ﬂow velocity; PVD, diastolic pulmonary venous ﬂow
velocity; PVA, pulmonary venous atrial reversal ﬂow velocity; MAM, mitral annular motion; TAM, tricuspid annular motion; s0 , peak systolic velocity; e0 , peak early
diastolic velocity; a0 , peak atrial systolic velocity; RVMPI, right ventricular myocardial performance index; RVH, right ventricular hypertrophy; BNP, brain natriuretic
peptide.
Fig. 3. Flowchart for the clinical, echocardiographic and electrocardiographic approach in patients with unexplained left ventricular hypertrophy. LVH, left ventricular
hypertrophy; TAM-e0 , peak early diastolic velocity of tricuspid annular motion; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease.
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annular plane systolic excursion and fractional area change; these
should be addressed in future research.
Conclusions
RV relaxation was found to deteriorate more in HCM than in
HHD, and TAM-e0 may be a useful index for differentiating HCM
from HHD.
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